文献库搜索 | GeneLibs

Jervis(Sarah),Song(Honglin),Lee(Andrew),Di... J Med Genet 2016-03-15

Although BRCA1 and BRCA2 mutations account for only ∼27% of the familial aggregation of ovarian cancer (OvC), no OvC ris...

Higgs(J E),Harkness(E F),Bowers(N L),Howar... J Med Genet 2016-06-02

...BRCA2, only 43/3245 (1.3%) carried BRCA2 c.9976A>T alone, after excluding individuals with BRCA2c.6275_6276delTT (n=22) ...

Uehara(Yuriko),Oda(Katsutoshi),Ikeda(Yuji)... PLoS One 2016-05-02

...BRCA2 (62%) coexisted with LOH of RB1 and TP53. Microarray analysis classified CCCs into three clusters. One cluster (CC...

Schroeder(Christopher),Faust(Ulrike),Sturm... Breast Cancer Res Treat 2016-03-04

...BRCA2 (27/620), 0.97 % in CHEK2 (6/620), 0.65 % in ATM (4/620), 0.48 % in CDH1 (3/620), 0.32 % in PALB2 (2/620), 0.32 % ...

Golmard(L),Delnatte(C),Laugé(A),Moncoutier... Oncogene 2016-07-25

BRCA1 and BRCA2 are the two major genes predisposing to breast and ovarian cancer. Whereas high de novo mutation rates h...

Pölsler(Laura),Fiegl(Heidi),Wimmer(Kathari... Eur J Hum Genet 2016-10-07

Screening for founder mutations in BRCA1 and BRCA2 has been discussed as a cost-effective testing strategy in certain po...

Xu(Lingyun),Zhao(Yansheng),Chen(Zhiqiang),... Breast Cancer 2016-04-25

...BRCA2, the present meta-analysis was addressed to determine whether adjuvant tamoxifen treatment for breast cancer is as...

Stukova(Marina),Hall(Matthew D),Tsotsoros(... J Inorg Biochem 2016-03-14

...BRCA2 mutations were hypersensitive to the PARP inhibitors olaparib and velaparib, but all other cell lines expressing f...

Klonowska(Katarzyna),Ratajska(Magdalena),C... Sci Rep 2016-03-28

...BRCA2. One of the most extensively studied candidates for breast and/or ovarian cancer susceptibility is BARD1. Although...

Trujillano(Daniel),Weiss(Maximilian E R),S... J Mol Diagn 2016-04-25

...BRCA2 mutations and polymorphisms. Genomic DNA was amplified using the Ion AmpliSeq BRCA1 and BRCA2 panel. The DNA Libra...